2023 Pediatric Rheumatology Symposium

March 29-April 1, 2023. New Orleans, LA.

View by Number View by Title View Sessions

View by Date

Thursday, March 30, 2023

2:30PM-3:30PM: Abstract Number: 004

Analysis of Patients with Juvenile Dermatomyositis Compared to Healthy Controls Using CITE-seq Identifies Differences in Cell Composition and Gene and Epitope Expression

Plenary Abstracts Session I

2:30PM-3:30PM: Abstract Number: 003

Inflammation or Infection? Understanding Linguistic and Cultural Nuances Impacting the Care of Somali Children with Juvenile Idiopathic Arthritis

Plenary Abstracts Session I

2:30PM-3:30PM: Abstract Number: 002

Re-analysis of the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Trial Identifies Novel Determinants of Patient Heterogeneity and a Distinct Lipid Metabolomic Signature of Atherosclerosis Progression

Plenary Abstracts Session I

2:30PM-3:30PM: Abstract Number: 001

Serious Infections Among Children with Systemic Lupus Erythematosus in the Pediatric Health Information System

Plenary Abstracts Session I

5:10PM-5:40PM: Abstract Number: 013

Applying Pathway Analysis to Whole Genome Data to Identify Pathophysiologic Pathways in Childhood-onset Systemic Lupus Erythematosus

Poster Breakout 1 - Lupus: Genetics, Epigenetics, & Social Determinants

5:10PM-5:40PM: Abstract Number: 014

Characterizing Lupus in African American Children in Southern United States

Poster Breakout 1 - Lupus: Genetics, Epigenetics, & Social Determinants

5:10PM-5:40PM: Abstract Number: 019

Developing Standard Improvement Curves for Disease Activity, Pain and Quality of Life in Children with Newly Diagnosed Juvenile Idiopathic Arthritis: Results from the CAPRI Registry

Poster Breakout 2 - JIA & Uveitis: Genetics, Clinical & Therapeutic Aspects

5:10PM-5:40PM: Abstract Number: 021

Distinguishing Childhood Sjogren’s Disease in Patients Presenting with Recurrent Sialadenitis in a Multidisciplinary Clinic

Poster Breakout 3 - Pediatric Rheumatology Potpourri

5:10PM-5:40PM: Abstract Number: 023

Effect of Type 1 Interferons and JAK Inhibitors on Gene Expression in Bioengineered Pediatric Skeletal Muscle

Poster Breakout 3 - Pediatric Rheumatology Potpourri

5:10PM-5:40PM: Abstract Number: 024

Effects of Corticosteroids on Central Nervous System Microvascular Properties Assessed by Neuroimaging

Poster Breakout 3 - Pediatric Rheumatology Potpourri

5:10PM-5:40PM: Abstract Number: 015

Epigenetically-Distinct B Cell Profiles Pre- and Post-Induction Therapy in Pediatric Lupus

Poster Breakout 1 - Lupus: Genetics, Epigenetics, & Social Determinants

5:10PM-5:40PM: Abstract Number: 016

Gene Expression Changes in Polyarticular Juvenile Idiopathic Arthritis Following Tofacitinib Treatment

Poster Breakout 2 - JIA & Uveitis: Genetics, Clinical & Therapeutic Aspects

5:10PM-5:40PM: Abstract Number: 020

Generation of Human Resident Memory T Cells in 3D Synovial Organoid Model

Poster Breakout 2 - JIA & Uveitis: Genetics, Clinical & Therapeutic Aspects

5:10PM-5:40PM: Abstract Number: 022

Narrative Medicine and Pediatric Rheumatology: Addressing Burnout and Bias

Poster Breakout 3 - Pediatric Rheumatology Potpourri

5:10PM-5:40PM: Abstract Number: 025

Patient- and Center-level Risk Factors for Research Lost to Follow-up Using the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

Poster Breakout 3 - Pediatric Rheumatology Potpourri

1
2
3
…
5
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].